Provectus Biopharmaceuticals, Inc.
PVCT
$0.05
$0.00-0.75%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 23.86% | -10.77% | 11.16% | 27.73% | -59.14% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.43% | 3.64% | -4.93% | 5.15% | -2.94% |
| Change in Net Operating Assets | -50.09% | 39,156.25% | -101.01% | -84.02% | 482.90% |
| Cash from Operations | -0.17% | 58.88% | -3.54% | -60.56% | 52.16% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 305.97% | -65.99% | 85.85% | -1.85% | 18.68% |
| Total Debt Repaid | 14.11% | 7.72% | -154.55% | 51.42% | 14.29% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -50.00% | -- | -- | -100.00% |
| Cash from Financing | 291.39% | -68.53% | 111.37% | 5.56% | -56.22% |
| Foreign Exchange rate Adjustments | -66.67% | 200.00% | -- | -100.00% | 300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,505.11% | -115.32% | 151.98% | -549.06% | -161.08% |